Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland R Griffiths

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Neuropharmacology|May 14, 2018
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances ActMatthew W Johnson, Roland R Griffiths, Peter S Hendricks, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 2, 2006
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHBLawrence P Carter, Brian D Richards, Miriam Z Mintzer, et al.
Journal of Psychopharmacology (Oxford, England)|January 19, 2017
An online survey of tobacco smoking cessation associated with naturalistic psychedelic useMatthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson, et al.
Psychopharmacology|January 22, 2017
Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratingsMary M Sweeney, Steven E Meredith, Daniel P Evatt, et al.
Journal of Caffeine Research|April 25, 2014
Caffeine Use Disorder: A Comprehensive Review and Research AgendaSteven E Meredith, Laura M Juliano, John R Hughes, et al.
Psychopharmacology|October 26, 2012
Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteersLawrence P Carter, Bethea A Kleykamp, Roland R Griffiths, et al.
Journal for the Scientific Study of Religion|January 15, 2013
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen PsilocybinKatherine A Maclean, Jeannie-Marie S Leoutsakos, Matthew W Johnson, et al.
Frontiers in Psychology|August 10, 2017
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy SessionsFrederick S Barrett, Hollis Robbins, David Smooke, et al.
The American Journal of Drug and Alcohol Abuse|March 2, 2019
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxietyAlan K Davis, Sara So, Rafael Lancelotta, et al.
Psychopharmacology|February 26, 2009
Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effectsStacey C Sigmon, Ronald I Herning, Warren Better, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Neuropharmacology|May 14, 2018
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances ActMatthew W Johnson, Roland R Griffiths, Peter S Hendricks, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 2, 2006
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHBLawrence P Carter, Brian D Richards, Miriam Z Mintzer, et al.
Journal of Psychopharmacology (Oxford, England)|January 19, 2017
An online survey of tobacco smoking cessation associated with naturalistic psychedelic useMatthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson, et al.
Psychopharmacology|January 22, 2017
Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratingsMary M Sweeney, Steven E Meredith, Daniel P Evatt, et al.
Journal of Caffeine Research|April 25, 2014
Caffeine Use Disorder: A Comprehensive Review and Research AgendaSteven E Meredith, Laura M Juliano, John R Hughes, et al.
Psychopharmacology|October 26, 2012
Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteersLawrence P Carter, Bethea A Kleykamp, Roland R Griffiths, et al.
Journal for the Scientific Study of Religion|January 15, 2013
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen PsilocybinKatherine A Maclean, Jeannie-Marie S Leoutsakos, Matthew W Johnson, et al.
Frontiers in Psychology|August 10, 2017
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy SessionsFrederick S Barrett, Hollis Robbins, David Smooke, et al.
The American Journal of Drug and Alcohol Abuse|March 2, 2019
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxietyAlan K Davis, Sara So, Rafael Lancelotta, et al.
Psychopharmacology|February 26, 2009
Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effectsStacey C Sigmon, Ronald I Herning, Warren Better, et al.
Pageof 14